Opening book details…
Can I read CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis on EtoBox?
CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis by L Leung; M Patel; S Teitsson; K Hofer; A Qian; M Kurt is a Economics, Econometrics and Finance article available to read on EtoBox.
What is CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis about?
Dupilumab improved asthma control and quality of life, regardless of baseline OCS starting dose. Improvements in AER continued during TRAVERSE and, as in VENTURE, dupilumab demonstrated persistently high reduction in OCS use without a tapering reduction schema.
Who reads CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis?
It is typically read by researchers, students, and practitioners in Economics, Econometrics and Finance.
- Author
- L Leung; M Patel; S Teitsson; K Hofer; A Qian; M Kurt
- Publisher
- Elsevier BV
- Published
- 2022
- Language
- EN
- Field
- Economics, Econometrics and Finance (Social Sciences)
More by L Leung; M Patel; S Teitsson; K Hofer; A Qian; M Kurt
Browse all works by L Leung; M Patel; S Teitsson; K Hofer; A Qian; M Kurt